Kenvue (NYSE:KVUE) Price Target Lowered to $18.00 at Evercore ISI

Kenvue (NYSE:KVUE) had its target price dropped by equities research analysts at Evercore ISI from $23.00 to $18.00 in a report released on Tuesday,Benzinga reports. The firm presently has an “in-line” rating on the stock. Evercore ISI’s price target would indicate a potential upside of 6.79% from the company’s previous close.

A number of other equities analysts have also recently weighed in on the company. UBS Group decreased their price objective on Kenvue from $25.00 to $23.00 and set a “neutral” rating on the stock in a report on Thursday, July 17th. Royal Bank Of Canada reduced their price target on Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a research report on Friday, August 8th. Barclays cut their price target on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating on the stock in a report on Tuesday, July 15th. JPMorgan Chase & Co. cut their price target on shares of Kenvue from $27.00 to $26.00 and set an “overweight” rating on the stock in a report on Friday, July 25th. Finally, Canaccord Genuity Group cut their price target on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Four analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $23.32.

Kenvue Price Performance

Shares of KVUE opened at $16.86 on Tuesday. Kenvue has a 52-week low of $16.53 and a 52-week high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. The business’s 50 day moving average price is $20.59 and its two-hundred day moving average price is $21.93. The firm has a market cap of $32.35 billion, a PE ratio of 22.78, a price-to-earnings-growth ratio of 2.48 and a beta of 0.83.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. During the same period in the prior year, the firm earned $0.32 earnings per share. Kenvue’s revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities analysts anticipate that Kenvue will post 1.14 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in KVUE. Pittenger & Anderson Inc. purchased a new position in Kenvue during the first quarter valued at $30,000. Trust Co. of Vermont raised its stake in Kenvue by 266.8% during the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after buying an additional 1,150 shares during the last quarter. TruNorth Capital Management LLC purchased a new position in Kenvue during the first quarter valued at $36,000. Truvestments Capital LLC purchased a new position in shares of Kenvue in the first quarter worth $37,000. Finally, Clal Insurance Enterprises Holdings Ltd raised its stake in shares of Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after purchasing an additional 1,287 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.